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Abstract
Background: The benefits of some second-generation antipsychotics (SGAs) must be weighed against the
increased risk for diabetes mellitus. This study examines whether the association between SGAs and diabetes differs
by dose.
Methods: Patients were ≥18 years of age from three US healthcare systems and exposed to an SGA for ≥45 days
between November 1, 2002 and March 31, 2005. Patients had no evidence of diabetes before index date and no
previous antipsychotic prescription filled within 3 months before index date.
49,946 patients were exposed to SGAs during the study period. Person-time exposed to antipsychotic dose
(categorized by tertiles for each drug) was calculated. Newly treated diabetes was identified using pharmacy data
to determine patients exposed to anti-diabetic therapies. Adjusted hazard ratios for diabetes across dose tertiles of
SGA were calculated using the lowest dose tertile as reference.
Results: Olanzapine exhibited a dose-dependent relationship for risk for diabetes, with elevated and progressive
risk across intermediate (diabetes rate per 100 person-years = 1.9; adjusted Hazard Ratio (HR), 1.7, 95% confidence
interval (CI), 1.0-3.1) and top tertile doses (diabetes rate per 100 person-years = 2.7; adjusted HR, 2.5, 95% CI, 1.4-
4.5). Quetiapine and risperidone exhibited elevated risk at top dose tertile with no evidence of increased risk at
intermediate dose tertile. Unlike olanzapine, quetiapine, and risperidone, neither aripiprazole nor ziprasidone were
associated with risk of diabetes at any dose tertile.
Conclusions: In this large multi-site epidemiologic study, within each drug-specific stratum, the risk of diabetes for
persons exposed to olanzapine, risperidone, and quetiapine was dose-dependent and elevated at therapeutic
doses. In contrast, in aripiprazole-specific and ziprasidone-specific stratum, these newer agents were not associated
with an increased risk of diabetes and dose-dependent relationships were not apparent. Although, these estimates
should be interpreted with caution as they are imprecise due to small numbers.
Background
Atypical, or second-generation antipsychotics (SGAs)
represent an important advancement in the treatment of
psychiatric symptoms and may have fewer extrapyrami-
dal side effects than older antipsychotics [1]. However,
there is a growing body of literature concerning the asso-
ciation between certain SGAs and risk of type 2 diabetes
mellitus [2-9]. Studies regarding the effect of individual
SGAs on diabetes vary in their conclusions, case defini-
tions, and analytic approaches [10].
In a large study comparing the rate of treated diabetes in
patients exposed to individual antipsychotics, we found
that different SGAs were associated with varying levels of
diabetes risk, ranging from no detectable increased risk
(aripiprazole, risperidone, quetiapine and ziprasidone) to
significant increases in risk (olanzapine and clozapine) [8].
This study was the largest post-marketing study to include
newer atypical agents, aripiprazole and ziprasidone. Our
findings were consistent with the American Diabetes
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found no association between the newer SGAs, ziprasi-
done and aripiprazole, and diabetes risk [2]. A recent
study in Denmark conducted by Nielsen et al found a
reduced risk of diabetes among aripiprazole users [2,3]. In
addition, a study by Kessing et al found the risk of diabetes
increased with first- and second-generation anti-psychotic
polypharmacy [11]. However, the effect of SGA dose on
diabetes risk was not examined directly in these earlier
studies.
The purpose of this study was to examine whether any
association between SGAs (aripiprazole, clozapine, olan-
zapine, risperidone, quetiapine, ziprasidone) and diabetes
mellitus differs according to dose.
Methods
The study population was formed using administrative
and healthcare claims data from three United States (US)
sites: (1) Kaiser Permanente Health Plan (Kaiser Perma-
nente) (Northern California; 2.9 million covered lives dur-
ing the study period); (2) HealthCore Integrated Research
Network (HealthCore) (14.5 million covered lives in health
plans across the US) and (3) PharMetrics (43 million cov-
ered lives from 73 health plans across the US). These sites
were chosen because they maintain extensive electronic
databases, including outpatient pharmacy, and inpatient
and outpatient encounter and claims records. Outpatient
pharmacy data include date of prescription fill, drug name,
dose per pill, number of pills dispensed, and days-supply.
While the electronic format of data from each site chosen
is not identical, the principal investigators of this study fol-
lowed a common protocol for collecting study data, have
extensive experience compiling data from these multiple
sources, have developed the site-specific algorithms
needed to construct a single, uniform analytic dataset, and
have established data management and quality control
checks. A limited data set (defined by the Health Insur-
ance Portability and Accountability Act (HIPAA) of 1996)
was used and all researchers had HIPAA-required busi-
ness associate and data use agreements in place before
conducting the research. This study was approved by the
Kaiser Permanente Northern California Institutional
Review Board (IRB) and deemed IRB exempt at Health-
Core and PharMetrics.
Study Population
Patients ≥ 18 years of age, newly exposed to SGAs
between November 1, 2002 and March 31, 2005 were
included in the cohort. This inception cohort consisted of
all patients exposed to an SGA for at least 45 days and
continuously enrolled for at least 3 months before and 6
months after the date of first prescription (index date)
with no evidence of diabetes using all available historical
data prior to the index date and no previous antipsychotic
prescription (first generation or SGA) filled within 3
months of the index date.
Exclusion of Patients with Previous History of Diabetes
Mellitus
Previous history of diabetes used all available historic
data and was defined using the following criteria: (1) at
least one emergency department visit with an Interna-
tional Classification of Diseases, 9th Revision (ICD-9)
coded diagnosis indicative of diabetes (250.xx); or (2) at
least two outpatient visits coded with diabetes (250.xx);
or (3) at least one inpatient stay with an ICD-9 coded
diagnosis indicative of diabetes (250.xx); or (4) filled at
least one prescription for an oral anti-diabetic agent or
insulin. Diagnosis codes or medication utilization were
used as exclusion criteria to provide a conservative
approach to excluding patients with a previous history
of diabetes.
Classification of Antipsychotic Exposure
Data analysis accounted for drug switching and non-
consistent use of drug treatment by categorizing person-
time exposed to individual antipsychotic agents. Patients
contributed exposed person-time to individual antipsy-
chotics beginning 45 days after index date, continuing
for the duration of the days-supply for an individual
prescription. Person-time accumulated, as described pre-
viously, until the first of the following occurred: (1)
patient switched to a different antipsychotic; (2) pre-
scription filled for anti-diabetic pharmacotherapy; (3)
disenrollment from health plan; (4) death; (5) end of
study period. Exposed person-time categories were
formed for aripiprazole, olanzapine, risperidone, ziprasi-
done, and quetiapine. Clozapine was not included due
to insufficient numbers.
Daily dose prescribed for each agent was calculated by
multiplying number of pills dispensed by dose per pill,
divided by days supply for that prescription episode.
Blinded to study outcome and exposure, the following
decision rules were applied to tabulate dosing episodes
to determine whether decision-rule modification was
necessary:
1. If patient received consecutive prescriptions for
the same dose of medication, but the prescription
was filled within (+/-) 14 days of the claims start/
end date, the gaps were bridged and patient was
classified as continuously exposed to the prescribed/
recorded dose.
2. If patient filled 2 or more prescriptions on the
same day, with the same days-supply and same dose,
the days-supplies were summed.
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same day, with the same dose but different days-sup-
ply recorded, the days-supplies were summed.
4. If patient filled 2 or more prescriptions on the
same day, with different doses:
a. If the days-supply between prescriptions was
within (+/-) 14 days, daily dose was summed
to the maximum days-supply between the 2
prescriptions.
b. If the days-supply between prescriptions was
greater than 14 days, dose was considered
switched to the second prescription strength
(after 14 days).
c. If the days-supplies were equal, daily dose was
summed.
d. If the days-supplies were equal and there were
≥2 records on the same day (e.g. record one–100
mg/30 days, 200 mg/30 days; record two–100 mg/
30 days, 200 mg/30 days), we summed the daily
dose and divided by the number of records and
summed the days-supply (e.g. 300 mg/60 days).
Using these decision rules, we obtained (blinded) clini-
cal input to determine whether data/decision rules
reflected expected clinical dosing distributions. The dos-
ing distributions for each drug were reviewed by a team
of clinical experts consisting of two clinicians (one clini-
cian was the study sponsor lead; the second clinician
was an outside academic consultant), and three PhD-
level epidemiologists (two epidemiologists were from the
contract research organization and the third represented
the study sponsor). To determine dosing distributions,
each expert team member was provided a distribution
of the dosing for each drug in the study. Blinded to
study outcome, the team collectively reviewed the distri-
bution for each drug and determined–based on clinical
and statistical judgment–that tertile categorization was
appropriate because the distribution of outcomes was
too sparse to allow more granular analyses. The team
addressed and deleted extreme outliers in dosing (e.g.,
clinically implausible doses indicative of data entry
errors).
Study Outcome (Newly Treated Diabetes)
Patients exposed to SGAs for at least 45 days during the
period January 1, 2002 through March 31, 2005 were
identified and followed for the outcome of treated dia-
betes. To ensure ample exposure for evaluation, indivi-
d u a l sw e r ef o l l o w e df r o mt h e4 5
th day after index date
through the earliest of the following events: (1) prescrip-
tion filled for anti-diabetic pharmacotherapy; (2) disen-
rollment from database/health plan; (3) death; (4) end of
study period.
Statistical Methods
Current daily antipsychotic dose (categorized by tertiles
for each drug; quantified in person-time) was calculated
as a time-dependant covariate (i.e. dose could change
over follow-up time). Newly treated diabetes mellitus
was identified using pharmacy data to determine
patients exposed to anti-diabetic therapies. Hazard ratios
(HRs) for diabetes across dose tertiles for each SGA
were calculated via Cox proportional hazards regression
using the lowest dose tertile as the reference, and
adjusting for age, sex, study site, year of cohort entry,
history of antipsychotic use (>3 months prior to index),
exposure to other pharmacotherapy (alpha blockers,
beta blockers, statins, corticosteroids, fibrates, lithium,
oral contraceptives). We fit separate models for each
SGA. Tests for trend across dose within each SGA were
performed by coding increasing dose as 1, 2, and 3 and
treating as a continuous variable in the Cox regression
model.
Results
The mean age of patients was 44 years, and 40 percent
were male; exposure to beta blockers, systemic corticos-
teroids, and valproate were most common, and 5% of
patients were obese according to ICD-9 codes (Table 1).
The rate and hazard ratios of treated diabetes in
patients exposed to SGAs by dose and drug are reported
in Table 2. Olanzapine exhibited a dose-dependent asso-
ciation with rate of diabetes (compared to the lowest
tertile (<5 mg)): HR = 2.5 for the highest tertile (≥ 10
mg) (95% CI 1.4, 4.5); and HR = 1.7 for the intermediate
tertile (5-<10 mg) (95% CI 1.0, 3.1). Quetiapine and ris-
peridone exhibited elevated rates at the top tertile doses
when compared to the lowest tertile: quetiapine (>150
mg vs. ≤ 50 mg) HR = 2.5 (95% CI 1.3, 4.7); risperidone
(≥ 2 mg vs. < 1 mg) HR = 2.1 (95% CI 1.0, 4.4). No evi-
dence of increased rate of diabetes was observed for
quetiapine and risperidone at the intermediate dose ter-
tile. Although the estimates are imprecise for the newer
SGAs aripiprazole and ziprasidone, there was no evi-
dence of dose dependence or elevated rate of new onset
diabetes in these agents.
Discussion
In this large, multi-site epidemiologic study, the risk of
diabetes for persons exposed to olanzapine, quetiapine,
and risperidone appears to be dose-dependent. Quetia-
pine and risperidone exhibited elevated risk at top tertile
doses, but no evidence of increased risk at the inter-
mediate dose tertile. Consistent with dosing guidelines
and the literature, the top tertile doses for quetiapine
and risperidone are indicated for treatment of schizo-
phrenia, bipolar disorder and depression [2,3,12-14].
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(i.e. sedation, irritability) [14,15]. Unlike olanzapine, que-
tiapine, and risperidone, aripiprazole and ziprasidone did
not exhibit a dose dependent association with diabetes.
Of note, the baseline (reference) diabetes rate was simi-
lar for all study SGAs except ziprasidone (where num-
bers were limited).
This study is subject to several limitations. Given sam-
ple size limitations for the newer agents, aripiprazole
and ziprasidone, precision in hazard ratio estimation is
low. As more individuals are exposed to these agents
over time, more precise estimates can be made. How-
ever, our findings are consistent with a recent study by
Guo which utilized different dosing cut points in a dif-
ferent population and found similar estimates for these
newer agents [16]. While it is likely that patients with
more severe psychiatric disease receive higher doses of
SGAs and this could potentially lead to confounding by
indication, the impact may be minimized through nor-
malization of the dosing across medications using clini-
cally significant tertile cut points. This study is subject
to the limitations inherent in using administrative data-
bases. Prescribed daily dose was not available; instead,
daily dose was calculated using an approach commonly
utilized in analyses of dose from administrative data-
bases. Due to data availability and quality, this study
does not include inpatient prescriptions. As a result,
hospitalized patients receiving specific SGAs were not
included. The incidence of diabetes may be underesti-
mated, as a result. However, the relative effect estimates
should be the same if hospitalization does not differ by
medication. Given that the inception cohort was formed
using a 3-month window of no evidence of previous
antipsychotic exposure, it is possible that patients with
previous antipsychotic exposure were included. In addi-
tion, we were unable to evaluate polypharmacy, a factor
shown by Kessing et al to be associated with diabetes
Table 1 Demographic and Clinical Characteristics of
Patients Exposed to Atypical Antipsychotics, November
2002-March 2005 (N = 49,946)
Characteristic N (%)
Sex
Male 19,981 (40.0)
Age (mean (s.d.
a)) 43.9 (19.2)
Index Year
2002 5,407 (10.8)
2003 24,438 (48.9)
2004 18,186 (36.4)
2005 1,914 (3.8)
Past use of antipsychotics
Aripiprazole 1,966 (3.9)
Clozapine 60 (0.1)
Olanzapine 13,826 (27.7)
Quetiapine 10,632 (21.3)
Risperidone 11,367 (22.8)
Ziprasidone 1,367 (2.7)
First generation antipsychotics (typicals) 1,714 (3.4)
Pharmacotherapy exposure
b
Alpha blockers 1,975 (4.0)
Beta blockers 9,479 (19.0)
Systemic corticosteroids 12,254 (24.5)
Fibrates 960 (1.9)
Lithium 6,662 (13.3)
Nogesterol oral contraceptives 487 (1.0)
Statins 5,171 (10.4)
Thiazide diuretics 7,561 (15.1)
Thiazide-related diuretics 219 (0.4)
Valproate 10,314 (20.7)
Hydantoin anticonvulsants 1,020 (2.0)
ICD-9 coded comorbidity
Obese 2531 (5.1)
a s.d. = standard deviation
b variables included in parent study
8
Table 2 Rate and Hazard Ratios of Treated Diabetes in Patients Exposed to Second-Generation Antipsychotics
a,B y
Dose
b and Drug
Dose category Patients exposed (N) Events (N) Person-years Diabetes rate
(per 100 person-years)
Adjusted
c HR
d
(95% CI
e)
Aripiprazole p
f = 0.43
≥15 mg 1321 4 371 1.1 1.3 (0.1, 12.2)
10 - <15 mg 988 1 214 0.5 0.6 (0.04, 9.8)
<10 mg 788 1 145 0.7 Reference
Olanzapine p
f = 0.002
≥10 mg 5921 58 2176 2.7 2.5 (1.4, 4.5)
5 - <10 mg 6761 41 2118 1.9 1.7 (1.0, 3.1)
<5 mg 4398 15 1361 1.1 Reference
Quetiapine p
f = 0.007
>150 mg 4686 34 1686 2.0 2.5 (1.3, 4.7)
51 -150 mg 5525 15 1610 0.9 1.2 (0.6, 2.5)
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in patients exposed to the newer agents (i.e. aripiprazole
or ziprasidone), this may bias the results. This study is
also subject to limitations inherent in observational stu-
dies including confounding, for example between higher
doses and more severe illness where medical co-morbid-
ity may be more common. However, given that analyses
included internal comparisons (i.e., within-drug compar-
isons), confounding is likely minimal.
Conclusions
This study suggests a dose-response relationship between
certain SGAs and risk of diabetes mellitus. However, the
number of patients exposed to the newer antipsychotics
(aripiprazole and ziprasidone) is limited, resulting in
reduced precision in hazard ratio estimates. Future goals
include updating this sample to obtain greater precision
around the estimates for the two newer agents, aripipra-
zole and ziprasidone.
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